Drug & intervention
pemetrexed
RxCUI 68446
RxNorm ingredient and formulation relationships
Source-verified product relationships. Every strength, delivery form and RxCUI remains a separate clinical concept.
Loading RxNorm relationships…
Background context
Pemetrexed
Pemetrexed, sold under the brand name Alimta among others, is a chemotherapy medication for the treatment of pleural mesothelioma and non-small cell lung cancer (NSCLC). It is available as a generic medication.
Background only. Canonical identity remains RxNorm; clinical-trial relationships come from ClinicalTrials.gov.Clinical trials
40 shownA Study To Assess the Safety, Tolerability, and Efficacy of Imzokitug in Combination With Pumitamig and Platinum-Doublet Chemotherapy (PDCT) Versus Pumitamig and PDCT as First-line Treatment for Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)NCT07680764 · 2026-09-10
RECRUITINGA Study of Neoadjuvant Amivantamab With Either Lazertinib or Chemotherapy in Participants With Resectable EGFR-Mutated NSCLCNCT07586202 · 2026-07-28
RECRUITINGA Study of BMS-986504 Monotherapy and in Combination With Other Agents in Participants With Advanced and/or Metastatic Solid Tumors With Homozygous MTAP Deletion (MountainTAP-5)NCT07492680 · 2026-07-27
RECRUITINGA Study of BL-B01D1 in Combination With Osimertinib as Perioperative Therapy in Patients With EGFR-mutated Resectable Non-small Cell Lung Cancer(PANKU-Lung09)NCT07642024 · 2026-07-24
RECRUITINGBeamion 44: A Study to Test How Well Zongertinib is Tolerated by People With Advanced Non-small Cell Lung Cancer With HER2 Mutations When Given in Combination With Chemotherapy With or Without PembrolizumabNCT07486817 · 2026-06-04
RECRUITINGSCTB41 Combined With Chemotherapy in Advanced Squamous Non-Small Cell Lung CancerNCT07662395 · 2026-05-09
RECRUITINGIvonescimab Alone And With Carboplatin/Pemetrexed For NSCLCNCT07405190 · 2026-05-01
RECRUITINGA Study to Compare the Combination of Navlimetostat (BMS-986504) With Pembrolizumab and Chemotherapy Versus Placebo Plus Pembrolizumab and Chemotherapy in First-line Metastatic Non-small Cell Lung Cancer Participants With Homozygous MTAP DeletionNCT07063745 · 2026-01-02
RECRUITINGSacituzumab Govitecan and Intrathecal Chemotherapy for Treating Leptomeningeal Metastases From Her2-negative Breast CancerNCT06462092 · 2026-01-01
RECRUITINGA Platform Study in Non-Small Cell Lung Cancer (NSCLC)NCT06996782 · 2025-11-24
RECRUITINGStudy of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)NCT07100080 · 2025-11-05
RECRUITINGA Phase Ib Clinical Study on the Safety and Efficacy of HC010 Combined With Chemotherapy in Lung CancerNCT07381829 · 2025-10-27
RECRUITINGStudy of Trastuzumab Deruxtecan, Pembrolizumab, and Platinum-based Chemotherapy in First-line HER2 Overexpressing Non-small Cell Lung CancerNCT06899126 · 2025-10-24
RECRUITINGA Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung CancerNCT06793215 · 2025-10-24
RECRUITINGA Clinical Study of Calderasib (MK-1084) and Other Treatments for Participants With Non-Small Cell Lung Cancer (MK-1084-007/KANDLELIT-007)NCT07190248 · 2025-10-08
RECRUITINGA Study of BL-M07D1 vs Pembrolizumab-platinum Chemotherapy in First-line Treatment of HER2-mutant Advanced or Metastatic Non-squamous NSCLCNCT07178795 · 2025-09-29
RECRUITINGIntrathecal Pemetrexed for Leptomeningeal Metastasis From Lung Adenocarcinoma That Progressed After Osimertinib.NCT06296745 · 2025-09-01
RECRUITINGIBI363 Combined With Chemotherapy or Pembrolizumab Combined With Chemotherapy as Neoadjuvant Therapy in Resectable Stage IB-III Non-Squamous Non-Small Cell Lung CancerNCT07122687 · 2025-08-26
RECRUITINGA Study to Assess Adverse Events, Change in Disease Activity of Intravenous Telisotuzumab Adizutecan in Combination With Osimertinib as First-Line Treatment in Adult Participants With Locally Advanced Unresectable or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung CancerNCT07005102 · 2025-08-03
RECRUITINGDZD6008 Combination Therapy in Patients With Locally Advanced or Metastatic NSCLC With EGFR Mutation (TIAN-SHAN7)NCT07070440 · 2025-07-16
RECRUITINGProspective Trial Assessing Real World Outcomes Response to Pembro in Black Patients w/ NSCLCNCT06745882 · 2025-06-13
RECRUITINGDISCERN: Dual Versus Single ICB in PDL-1 Negative NSCLCNCT06364917 · 2025-05-30
RECRUITINGAK129 Combination Therapy for Advanced Solid TumorsNCT06943820 · 2025-05-21
RECRUITINGA Study on the Efficacy and Safety of Golidocitinib Combined With Tislelizumab and Chemotherapy as First-line Treatment for Advanced NSCLCNCT06969612 · 2025-05-15
RECRUITINGA Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)NCT06875310 · 2025-04-24
RECRUITINGA Study to Evaluate the Efficacy and Safety of Glumetinib Combined With Osimertinib Mesylate Versus Platinum-based Doublet Chemotherapy in Non-Small Cell Lung Cancer Patients After Resistance to EGFR-TKIsNCT06829459 · 2025-04-03
RECRUITINGBBO-11818 in Adult Subjects With KRAS Mutant CancerNCT06917079 · 2025-03-31
RECRUITINGA Study of Pembrolizumab With or Without Chemotherapy in Combination With Additional Treatments for Advanced Non-Small Cell Lung Cancer (NSCLC) (MK-3475-01G/KEYMAKER U01)NCT06731907 · 2025-03-30
RECRUITINGPhase III Trial of SYS6010 Versus Platinum-based Chemotherapy for EGFR-mutated NSCLC（SYNSTAR01）NCT06927986 · 2025-03-30
RECRUITINGPhase II Clinical Study of JS207 (PD-1/VEGF Bispecific Antibody) Combination Therapies in Patients With Driver Gene-Positive, Advanced Non-Small Cell Lung Cancer After Failure of TKI TherapyNCT06868836 · 2025-03-30
RECRUITINGStudy to Evaluate Adverse Events and Efficacy of Intravenous (IV) Telisotuzumab Adizutecan in Combination With a PD-1 Immune Checkpoint Inhibitor in Adult Participants With Advanced or Metastatic Non-Squamous NSCLC With No Prior Treatment for Advanced Disease, and No Actionable Genomic AlterationsNCT06772623 · 2025-03-06
RECRUITINGA Clinical Study to Evaluate the Safety and Tolerability of AWT020 in Patients With Advanced MalignanciesNCT06839105 · 2025-02-21
RECRUITINGA Study to Evaluate Efficacy, and Safety of QL2107 Plus Chemo and Compare With Keytruda in Participants With IV nqNSCLCNCT06754644 · 2025-01-15
RECRUITINGSafety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung CancerNCT06712316 · 2025-01-07
RECRUITINGLUNG-05: Investigating Chemotherapy Effectiveness for Non-Small Cell Lung Cancer (NSCLC) Metastatic PatientsNCT06576635 · 2024-12-16
RECRUITINGIntrathecal Injection Pemetrexed And Bevacizumab in Patients With Leptomeningeal Metastases in NSCLCNCT06663306 · 2024-12-09
RECRUITINGA Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Non-Squamous NSCLCNCT06627647 · 2024-11-27
RECRUITINGA Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)NCT06623422 · 2024-10-21
RECRUITINGA Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1%NCT06561386 · 2024-10-07
RECRUITINGA Study to Investigate the Efficacy and Safety of Dato-DXd With or Without Osimertinib Compared With Platinum Based Doublet Chemotherapy in Participants With EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung CancerNCT06417814 · 2024-10-04
RECRUITINGConditions being studied
Non-small Cell Lung Cancer129Non Small Cell Lung Cancer62Carcinoma, Non-Small-Cell Lung60Lung Cancer45Nsclc17Non-Squamous Non-Small Cell Lung Cancer15Non-Small-Cell Lung Cancer13Stage IV Lung Cancer AJCC v812Breast Cancer11Stage IIIB Lung Cancer AJCC v811Metastatic Non-Small Cell Lung Cancer10Non-small Cell Lung Cancer (NSCLC)10Stage IIIA Lung Cancer AJCC v810Lung Neoplasms9Mesothelioma9Non-Small Cell Lung Cancer Metastatic9Stage III Lung Cancer AJCC v89Stage IIIC Lung Cancer AJCC v89Stage IVA Lung Cancer AJCC v89Stage IVB Lung Cancer AJCC v89
Research locations
Leading sponsors
Eli Lilly and Company75Merck Sharp & Dohme LLC30AstraZeneca22Hoffmann-La Roche21Bristol-Myers Squibb19National Cancer Institute (NCI)10M.D. Anderson Cancer Center9Memorial Sloan Kettering Cancer Center9Novartis Pharmaceuticals8SCRI Development Innovations, LLC8Boehringer Ingelheim7Tianjin Medical University Cancer Institute and Hospital7AbbVie6Incyte Corporation6Innovent Biologics (Suzhou) Co. Ltd.6
Drug identity and terminology: RxNorm. Trial relationships: ClinicalTrials.gov.